SPX4,274.04-31.16 -0.72%
DIA340.20-1.54 -0.45%
IXIC12,938.12-164.43 -1.25%

BRIEF-Ionis Announces Positive Topline Results From Phase 2B Clinical Study Of Fesomersen, A Potential Novel Anti-Thrombotic Treatment

BRIEF-Ionis Announces Positive Topline Results From Phase 2B Clinical Study Of Fesomersen, A Potential Novel Anti-Thrombotic Treatment

Reuters · 07/28/2022 07:42
BRIEF-Ionis Announces Positive Topline Results From Phase 2B Clinical Study Of Fesomersen, A Potential Novel Anti-Thrombotic Treatment

Ionis Pharmaceuticals Inc IONS:

  • IONIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2B CLINICAL STUDY OF FESOMERSEN, A POTENTIAL NOVEL ANTI-THROMBOTIC TREATMENT

  • IONIS PHARMACEUTICALS INC - PHASE 2B RE-THINC ESRD STUDY OF FESOMERSEN MET ITS PRIMARY ENDPOINT IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

  • IONIS PHARMACEUTICALS INC - FESOMERSEN DEMONSTRATED SUBSTANTIAL AND STATISTICALLY SIGNIFICANT REDUCTIONS IN FACTOR XI ACTIVITY LEVELS

  • IONIS PHARMACEUTICALS INC - FESOMERSEN, A NOVEL FACTOR XI ANTISENSE INHIBITOR DESIGNED TO PREVENT THROMBOSIS, WAS SAFE AND WELL-TOLERATED IN STUDY WITH UP TO 48-WEEK

Source text for Eikon: ID:

Further company coverage: IONS